Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BTK inhibitor

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

After some big setbacks, Sanofi talks up its R&D portfolio

Hopes its pipeline of 71 projects delivers strong sales

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Sanofi launches French eHealth laboratory 39BIS

The digital lab will focus on its home market and is based near Paris

dengue fever mosquito

Sanofi confirms suspected safety issue with dengue vaccine

As rival Takeda conduct phase II testing for its own dengue vaccine candidate

- PMLiVE

Reading human behaviour to create a medical future

Sanofi's Dr Anne Beal and Dr Bernard Hamelin on unlocking the doors to patient behaviour

- PMLiVE

Uptake Strategies and Sanofi win capability development prize at PMEA

Judges praised their programme’s pragmatic design and huge scalability

- PMLiVE

Sanofi’s diabetes IMPACT programme wins at PMEA 2017

Takes home first place in Excellence in Demonstrating Economic and Societal Value

Sanofi reception

Sanofi licences Principia MS drug in $805m deal

Californian biotech is set to receive $765m plus in milestone payments if PRN2246 goes to market

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links